Rituximab and Belimumab Combination Therapy in PR3 Vasculitis (COMBIVAS)

  • days left to enroll
  • participants needed
  • sponsor
    Rachel Jones
Updated on 9 February 2022
microscopic polyangiitis
anti-neutrophil cytoplasmic antibody


Mechanistic study to assess whether dual B-cell immunotherapy by co-administration of rituximab and belimumab will result in improvements in biological endpoints, functional outcomes and clinical status compared to rituximab with placebo.

Condition ANCA Associated Vasculitis, Granulomatosis With Polyangiitis
Treatment Rituximab, Prednisolone, belimumab
Clinical Study IdentifierNCT03967925
SponsorRachel Jones
Last Modified on9 February 2022


Yes No Not Sure

Inclusion Criteria

Participants must be 18 of age
Have a diagnosis of AAV (granulomatosis with polyangiitis or microscopic polyangiitis)
Have PR3 ANCA positivity by ELISA at screening
Have active disease defined by one major or three minor disease activity items on BVAS/WG
Be capable of giving signed informed consent

Exclusion Criteria

MPO ANCA or anti-GBM antibody positivity by ELISA at screening
Presence of pulmonary haemorrhage with hypoxia at screening
Estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m2 at screening
Have an acute serious or chronic infection at screening
Have received any B cell targeted therapy within 364 days of Day 1
Have received any steroid injection (e.g., intramuscular [IM], intraarticular, or IV) within 60 days of Day 1 (unless given during or 14 days before screening period)
Have received >1.5mg methylprednisolone (IV) between 14 days prior to screening and Day 1 (including Day 1)
Have received oral prednisolone >10mg/day (or equivalent) on average over the 30 days prior to screening
Have undetectable peripheral blood B cells at screening
Have IgG <400mg/dl at screening
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note